Ghana and Egypt have agreed to streamline the registration of Egyptian pharmaceutical products in Ghana as the two countries seek to deepen economic cooperation and improve access to medicines. Corrections Policy
The agreement was reached during a bilateral meeting between President John Dramani Mahama and Egyptian President Abdel Fattah el-Sisi on the sidelines of the Eighth African Union Mid-Year Coordination Summit in Egypt.
President Mahama disclosed the development after the meeting, saying the two countries had agreed to facilitate the registration process for Egyptian pharmaceutical products entering the Ghanaian market.
“We agreed to streamline registration of Egyptian pharmaceutical products in Ghana to improve healthcare access and attract investment,” President Mahama said in a post following the engagement.
The agreement places pharmaceuticals among the key areas in which Ghana and Egypt intend to strengthen bilateral cooperation.
It comes at a time when both countries are seeking to expand trade and investment while leveraging their respective capabilities in strategic sectors.
For Ghana, improving access to quality and affordable medicines remains an important part of strengthening the country’s healthcare system.
A more efficient registration process could potentially make it easier for approved pharmaceutical products from Egypt to reach the Ghanaian market without compromising regulatory requirements. Editorial Ethics & Independence
Egypt has a well-developed pharmaceutical industry and is one of Africa’s significant producers of medicines. Increased cooperation could therefore create opportunities for Ghana to benefit from Egyptian manufacturing capacity, technical expertise and investment.
However, streamlining registration does not mean removing regulatory safeguards.
In Ghana, the Food and Drugs Authority (FDA) is responsible for regulating medicines and ensuring that pharmaceutical products available on the Ghanaian market meet required standards for safety, quality and efficacy.
The FDA’s Drug and Nutraceuticals Department processes applications for the registration and market authorization of medicines intended for sale or distribution in Ghana.
Its responsibilities include evaluating applications, maintaining the national drug register, issuing registration certificates and engaging stakeholders on pharmaceutical regulation.
The proposed cooperation could therefore focus on making regulatory procedures more efficient while maintaining the checks required to protect public health. Editorial Standards
The development also builds on existing regulatory engagement between Ghana and Egypt.
In April 2026, the Chairman of the Egyptian Drug Authority received the Chief Executive Officer of Ghana’s FDA as both countries explored ways to strengthen cooperation in pharmaceutical and regulatory matters.
The discussions included regulatory cooperation, exchange of expertise and efforts to support public health.
The latest political agreement between Presidents Mahama and el-Sisi could consequently provide further momentum for those regulatory discussions.
Beyond pharmaceuticals, the two leaders discussed a broader range of issues aimed at strengthening Ghana-Egypt relations.
President Mahama expressed appreciation to Egypt for its support for Ghana’s resolution on reparations at the United Nations and urged continued backing as international discussions on the issue progress.
The leaders also discussed defence and regional security cooperation. Ghana is interested in drawing on Egypt’s experience and capabilities in the defence sector, with proposed areas of cooperation including intelligence sharing, capacity building and counter-terrorism.
They further reaffirmed support for the Sahel-Gulf of Guinea Accord, which seeks to strengthen cooperation in addressing security challenges affecting countries across the region.
Infrastructure and urban development also featured in the discussions.
As Ghana considers plans for a new capital city and continues efforts to expand social housing, President Mahama indicated that Ghana could benefit from Egypt’s experience in developing large-scale infrastructure projects.
In particular, Ghana is interested in learning from Egypt’s development of its New Administrative Capital, a major urban development project designed to ease pressure on Cairo and establish a new administrative and commercial centre.
The pharmaceutical agreement is therefore part of a wider effort to strengthen practical cooperation between Accra and Cairo rather than an isolated trade arrangement.
For pharmaceutical manufacturers and investors, a clearer and more efficient regulatory pathway could make Ghana a more attractive destination for Egyptian pharmaceutical products and potentially encourage greater investment in the country’s healthcare and pharmaceutical sectors.
For Ghanaian consumers, the potential benefit would depend on how the agreement is implemented.
Faster registration could improve the availability of medicines, but the products must continue to meet Ghana’s regulatory standards before they are approved for the market.
Maintaining that balance between efficiency and safety will be critical. Pharmaceutical regulation exists to ensure that medicines entering the market are properly assessed and that patients are protected from products that may be unsafe, ineffective or of poor quality.
The agreement could also open opportunities for longer-term cooperation beyond the importation of finished medicines.
Greater engagement between Ghanaian and Egyptian pharmaceutical institutions could support technology transfer, investment, regulatory capacity building and eventually local pharmaceutical manufacturing. Newscard
For now, the focus is on streamlining the registration of Egyptian pharmaceutical products as both countries seek practical ways to translate their longstanding diplomatic relationship into stronger economic and healthcare cooperation.
The agreement between Presidents Mahama and el-Sisi signals renewed interest in using bilateral relations to address practical development needs, with pharmaceuticals emerging as one of the sectors capable of delivering direct benefits to citizens.
Its eventual impact will depend on the regulatory arrangements developed by the relevant institutions and the extent to which increased cooperation translates into greater access to safe, effective and affordable medicines for people in Ghana.